Ocugen Inc (OCGN) Stock Price, Quote & News

Company Profile

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber c...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 328 4701

Website: www.ocugen.com

Address:

11 Great Valley Parkway, Malvern, United States

happihourusa Oct. 5 at 12:59 AM

Sometimes everything happens for a reason, I really hope she hears about what $OCGN is doing https://www.cosmopolitan.com/entertainment/celebs/a68293896/madison-love-is-blind-season-9-diagnosis/

1 · Reply

icervantes Oct. 5 at 12:19 AM

$OCGN https://m.aktiencheck.de/news/PRNewswire-Ocugen_Shares_Surge_on_Pipeline_Progress_and_Strategic_Outreach-19073005

0 · Reply

skrimpthirty Oct. 4 at 11:50 PM

$OCGN does anyone know this person?😆 I'll give you 3 guesses. Who's first?

1 · Reply

Family143 Oct. 4 at 11:27 PM

$OCGN

1 · Reply

Hamiltoes Oct. 4 at 10:44 PM

$OCGN what are these bots trying to say?

2 · Reply

thegreenhammer Oct. 4 at 10:34 PM

$OCGN https://academic.oup.com/ooim/article/6/1/iqaf007/8241976?login=false

0 · Reply

thegreenhammer Oct. 4 at 10:34 PM

$OCGN https://academic.oup.com/ooim/article/6/1/iqaf007/8241976?login=false ocu500 🫢

0 · Reply

thegreenhammer Oct. 4 at 10:04 PM

$OCGN almost a month ago. 🤔

0 · Reply

thegreenhammer Oct. 4 at 9:23 PM

$OCGN I’m not going to say anything 🫣🫢😎

0 · Reply

Chino43101 Oct. 4 at 7:59 PM

$OCGN so 1.98 Monday then close 1.81. Then 2.04 and close 1.85 Tuesday. That's the trend. Let's go 🤷‍♂️🙂

1 · Reply

Ocugen: A Retinal Disease Juggernaut In The Making

Sep 15, 2025, 4:29 PM EDT - 19 days ago

Ocugen Shares Are Trading Higher Monday: What's Going On?

Sep 15, 2025, 6:03 AM EDT - 19 days ago

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Sep 2, 2025, 7:02 AM EDT - 4 weeks ago

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Aug 13, 2025, 6:27 AM EDT - 7 weeks ago

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Aug 12, 2025, 3:45 PM EDT - 7 weeks ago

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 8, 2025, 5:03 PM EDT - 2 months ago

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 1, 2025, 12:30 PM EDT - 2 months ago

Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 8:25 AM EDT - 2 months ago

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Jul 21, 2025, 7:30 AM EDT - 2 months ago

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Jul 18, 2025, 7:02 AM EDT - 2 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Jul 17, 2025, 6:30 AM EDT - 2 months ago

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Jun 23, 2025, 7:30 AM EDT - 3 months ago

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Jun 18, 2025, 4:00 PM EDT - 3 months ago

Ocugen: Three Potential Gene-Therapy Filings By 2028

Jun 16, 2025, 7:02 AM EDT - 3 months ago

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Jun 11, 2025, 7:30 AM EDT - 4 months ago

Ocugen To Present at BIO International Convention 2025

Jun 5, 2025, 7:02 AM EDT - 4 months ago

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

May 27, 2025, 7:02 AM EDT - 4 months ago

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 9, 2025, 10:02 AM EDT - 5 months ago

Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript

May 9, 2025, 8:01 AM EDT - 5 months ago

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 5 months ago

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Apr 29, 2025, 7:30 AM EDT - 5 months ago

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Apr 8, 2025, 8:02 AM EDT - 6 months ago

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Mar 18, 2025, 8:02 AM EDT - 7 months ago

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Mar 5, 2025, 10:59 AM EST - 7 months ago

Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 7:02 AM EST - 7 months ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 8:46 AM EST - 7 months ago

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Feb 21, 2025, 8:00 AM EST - 8 months ago

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Feb 12, 2025, 7:42 AM EST - 8 months ago

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Feb 3, 2025, 6:30 AM EST - 8 months ago

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Jan 27, 2025, 6:30 AM EST - 8 months ago

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Jan 16, 2025, 7:30 AM EST - 9 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Jan 13, 2025, 6:30 AM EST - 9 months ago

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

Dec 19, 2024, 6:38 AM EST - 10 months ago

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Dec 11, 2024, 7:02 AM EST - 10 months ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Nov 27, 2024, 7:09 AM EST - 11 months ago

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference

Nov 20, 2024, 7:30 AM EST - 11 months ago

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

Nov 19, 2024, 7:02 AM EST - 11 months ago

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Nov 8, 2024, 10:18 AM EST - 11 months ago

Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 6:45 AM EST - 11 months ago

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

Nov 7, 2024, 6:30 AM EST - 11 months ago

Ocugen Secures $30 Million in Debt Funding

Oct 28, 2024, 6:30 AM EDT - 1 year ago

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

Oct 22, 2024, 7:02 AM EDT - 1 year ago

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

Oct 17, 2024, 7:30 AM EDT - 1 year ago

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

Oct 9, 2024, 6:30 AM EDT - 1 year ago

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial

Oct 2, 2024, 6:30 AM EDT - 1 year ago

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa

Sep 24, 2024, 7:30 AM EDT - 1 year ago

Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm

Sep 17, 2024, 2:25 AM EDT - 1 year ago

Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3

Sep 9, 2024, 6:30 AM EDT - 1 year ago

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

happihourusa Oct. 5 at 12:59 AM

Sometimes everything happens for a reason, I really hope she hears about what $OCGN is doing https://www.cosmopolitan.com/entertainment/celebs/a68293896/madison-love-is-blind-season-9-diagnosis/

1 · Reply

icervantes Oct. 5 at 12:19 AM

$OCGN https://m.aktiencheck.de/news/PRNewswire-Ocugen_Shares_Surge_on_Pipeline_Progress_and_Strategic_Outreach-19073005

0 · Reply

skrimpthirty Oct. 4 at 11:50 PM

$OCGN does anyone know this person?😆 I'll give you 3 guesses. Who's first?

1 · Reply

Family143 Oct. 4 at 11:27 PM

$OCGN

1 · Reply

Hamiltoes Oct. 4 at 10:44 PM

$OCGN what are these bots trying to say?

2 · Reply

thegreenhammer Oct. 4 at 10:34 PM

$OCGN https://academic.oup.com/ooim/article/6/1/iqaf007/8241976?login=false

0 · Reply

thegreenhammer Oct. 4 at 10:34 PM

$OCGN https://academic.oup.com/ooim/article/6/1/iqaf007/8241976?login=false ocu500 🫢

0 · Reply

thegreenhammer Oct. 4 at 10:04 PM

$OCGN almost a month ago. 🤔

0 · Reply

thegreenhammer Oct. 4 at 9:23 PM

$OCGN I’m not going to say anything 🫣🫢😎

0 · Reply

Chino43101 Oct. 4 at 7:59 PM

$OCGN so 1.98 Monday then close 1.81. Then 2.04 and close 1.85 Tuesday. That's the trend. Let's go 🤷‍♂️🙂

1 · Reply

Fox1Fox2 Oct. 4 at 6:28 PM

$OCGN

2 · Reply

Hamiltoes Oct. 4 at 6:03 PM

$OCGN veri

2 · Reply

lorrimerjoli Oct. 4 at 6:03 PM

$OCGN Already did my DD and I'm seeing a nice risk-reward balance. Will take my initial position this Monday. Please bulls don't make it run so high yet and let me buy under $2!!

1 · Reply

Jangalang Oct. 4 at 5:50 PM

$OCGN … $2.00 Tuesday next week… Bullish AF

0 · Reply

jacksparo Oct. 4 at 5:43 PM

$GEVO $OCGN $BTBT $LAES Great week and the monthly chart is getting much better . Long term still my major opportunity here! I am preparing full updates for those to be shared in my email group soon!

0 · Reply

Dmonzzz93 Oct. 4 at 5:33 PM

$OCGN

0 · Reply

SIRWINSALOT Oct. 4 at 5:21 PM

$OCGN this is an incredibly wise statement! I agree with this and I think many many people will be surprised where we go and how big this gets and the comment about dividends or other massive things 100% possible! If it materializes as expected we will be essentially owning one of the largest Pharma stocks of the next decade currently under two dollars Imagine owning any of the top 50 stocks when they were startups and holding through their successes without taking your hundred percent gain or your thousand percent gain even I just can’t imagine selling this and taking my money to put it somewhere else when we haven’t even completed all of the stuff coming up so for that reason I will hold long and strong with the majority of my position because where else are we gonna put it that has a better opportunity than this?

0 · Reply

CaptSparow Oct. 4 at 5:18 PM

$OCGN Rational for $500 million up front ++ to Ocugen Suddenly that recent $15 price target ....

0 · Reply

CaptSparow Oct. 4 at 5:14 PM

$OCGN Rumor or speculation? Time will tell.

0 · Reply

CaptSparow Oct. 4 at 5:09 PM

$OCGN Pfizer or Novartis? Novartis or Pfizer? Pfizer or Novartis? Novartis or Pfizer? Pfizer or Novartis? Novartis or Pfizer? IYKYK

0 · Reply

zebo50 Oct. 4 at 4:29 PM

$OCGN $18 soon

0 · Reply

zebo50 Oct. 4 at 4:28 PM

$OCGN

1 · Reply

Market Cap	517.38M
Revenue (ttm)	4.06M
Net Income (ttm)	-54.05M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,331.28%
Debt to Equity Ratio	9.19

Volume	12,148,800
Avg Vol	4,056,130
Day's Range	N/A - N/A
Shares Out	292.31M
Stochastic %K	75%
Beta	4.20
Analysts	Strong Sell
Price Target	$6.50